Effects of Vasopressin in Septic Shock

Comparison of Vasopressin versus Norepinephrine in vascular damage biomarkers in patients with septic shock

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012100311002N1

Enrollment

Registered

2012-10-16

Start date

2012-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic shock. Septic shock

Interventions

Intervention 1: Group one will receive infusion of 0.01-0.03u/min of vasopressin. vasopressin infusions will titrate and tapered to maintain a target blood pressure. This intervention will continue fo

Treatment - Drugs

Group one will receive infusion of 0.01-0.03u/min of vasopressin. vasopressin infusions will titrate and tapered to maintain a target blood pressure. This intervention will continue for 48 hours

Group two will receive infusion of 5-15 mcg/min of norepinephrine. Norepinephrine infusions will titrate and tapered to maintain a target blood pressure. This intervention will continue for 48 hours

Eligibility

Sex/Gender

All

Age

16 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients older than 16 years of age who has septic shock that is resistant to fluids (as defined by lack of response to 500 ml of normal saline or a requirement for vasopressor) within 48 hours. Exclusion criteria: Patients less than 16 years of age; history of CHD; underlying chronic heart disease (NYHA class III or IV); severe hyponatremia (serum sodium less than 130 mEq/L); acute mesenteric ischemia; pregnancy; Patient or legal guardian does not consent for enrollment

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Tumor Necrosis Factor-Alpha. Timepoint: before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Elisa.;Interleukin-1. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Elisa.;Interleukin-6. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Elisa.;Pentraxin-3. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Elisa.;Angiopoietin-1. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: RIA.;Angiopoietin-2. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Elisa.;CRP. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Elisa.;Lactate. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Calorimetric assay.	—

Measure

Time frame

Tumor Necrosis Factor-Alpha. Timepoint: before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Elisa.;Interleukin-1. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Elisa.;Interleukin-6. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Elisa.;Pentraxin-3. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Elisa.;Angiopoietin-1. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: RIA.;Angiopoietin-2. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Elisa.;CRP. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Elisa.;Lactate. Timepoint: Before vasopressor administration and in 12 hours, 24 hours and 48 hours. Method of measurement: Calorimetric assay.

—

Secondary

Measure	Time frame
Mortality. Timepoint: Daily. Method of measurement: SAPSII.;Organ dysfunction. Timepoint: Daily. Method of measurement: MODS.;MAP. Timepoint: every 3 hours. Method of measurement: NIBP.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElchin Barzegar

Tehran University of Medical Sciences

elchin.barzegar@gmail.com+98 21 6695 4709

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026